Similar articles for PMID: 24412910

Year	Number of Results
1982	1
1987	1
1990	1
1996	1
2002	1
2004	2
2005	2
2006	7
2007	5
2008	2
2009	2
2010	5
2011	12
2012	9
2013	8
2014	7
2015	3
2016	9
2017	11
2018	7
2019	6
2020	6
2021	6
2022	2
2024	0

1

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.

Jolles S, Borte M, Nelson RP Jr, Rojavin M, Bexon M, Lawo JP, Wasserman RL. Jolles S, et al. Clin Immunol. 2014 Feb;150(2):161-9. doi: 10.1016/j.clim.2013.10.008. Epub 2013 Oct 26. Clin Immunol. 2014. PMID: 24412910 Free article. Clinical Trial.

2

Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

Niebur HB, Duff CM, Shear GF, Nguyen D, Alberdi TK, Dorsey MJ, Sleasman JW. Niebur HB, et al. Clin Exp Immunol. 2015 Sep;181(3):441-50. doi: 10.1111/cei.12623. Epub 2015 Jul 7. Clin Exp Immunol. 2015. PMID: 25761372 Free PMC article. Clinical Trial.

3

Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.

Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, Belohradsky BH, Wahn V, Neufang-Hüber J, Zenker O, Grimbacher B. Jolles S, et al. Clin Immunol. 2011 Oct;141(1):90-102. doi: 10.1016/j.clim.2011.06.002. Epub 2011 Jun 12. Clin Immunol. 2011. PMID: 21705277 Free article. Clinical Trial.

4

Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.

Krishnarajah G, Lehmann JK, Ellman B, Bhak RH, DerSarkissian M, Leader D Jr, Bullinger AL, Sheng Duh M. Krishnarajah G, et al. Am J Manag Care. 2016 Oct;22(15 Suppl):s475-s481. Am J Manag Care. 2016. PMID: 27849353 Free article.

5

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.

Mallick R, Jolles S, Kanegane H, Agbor-Tarh D, Rojavin M. Mallick R, et al. J Clin Immunol. 2018 Nov;38(8):886-897. doi: 10.1007/s10875-018-0562-3. Epub 2018 Nov 21. J Clin Immunol. 2018. PMID: 30465179 Free PMC article.

6

Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.

Stein MR, Koterba A, Rodden L, Berger M. Stein MR, et al. Postgrad Med. 2011 Sep;123(5):186-93. doi: 10.3810/pgm.2011.09.2474. Postgrad Med. 2011. PMID: 21904101

7

Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.

Jolles S, Sleasman JW. Jolles S, et al. Adv Ther. 2011 Jul;28(7):521-33. doi: 10.1007/s12325-011-0036-y. Epub 2011 Jun 14. Adv Ther. 2011. PMID: 21681653 Review.

8

Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.

Berger M, Murphy E, Riley P, Bergman GE; VIRTUE Trial Investigators. Berger M, et al. South Med J. 2010 Sep;103(9):856-63. doi: 10.1097/SMJ.0b013e3181eba6ea. South Med J. 2010. PMID: 20689467 Clinical Trial.

9

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

Canessa C, Iacopelli J, Pecoraro A, Spadaro G, Matucci A, Milito C, Vultaggio A, Agostini C, Cinetto F, Danieli MG, Gambini S, Marasco C, Trizzino A, Vacca A, De Mattia D, Martire B, Plebani A, Di Gioacchino M, Gatta A, Finocchi A, Licciardi F, Martino S, De Carli M, Moschese V, Azzari C. Canessa C, et al. Int J Immunopathol Pharmacol. 2017 Mar;30(1):73-82. doi: 10.1177/0394632016681577. Epub 2016 Dec 7. Int J Immunopathol Pharmacol. 2017. PMID: 27927705 Free PMC article.

10

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.

Jolles S, Rojavin MA, Lawo JP, Nelson R Jr, Wasserman RL, Borte M, Tortorici MA, Imai K, Kanegane H. Jolles S, et al. J Clin Immunol. 2018 Nov;38(8):864-875. doi: 10.1007/s10875-018-0560-5. Epub 2018 Nov 10. J Clin Immunol. 2018. PMID: 30415311 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

104 results

Results by year